|
13 Jan 2023 |
Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
|
|
10 Jan 2023 |
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
|
|
06 Jan 2023 |
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
|
|
06 Jan 2023 |
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
|
|
04 Jan 2023 |
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
|
|
28 Dec 2022 |
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
|
|
27 Dec 2022 |
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
|
|
22 Dec 2022 |
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
|
|
21 Dec 2022 |
Novel, personalized immunotherapy platform designed to achieve Trifecta of anti-cancer activity using unique bi-shRNA DNA-based plasmid and patient's own tumor tissue
|
|
21 Dec 2022 |
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
|
|
20 Dec 2022 |
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
|
|
15 Dec 2022 |
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met
|
|
15 Dec 2022 |
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
|
|
12 Dec 2022 |
Amphera Announces Clinical Updates of MesoPher Cell Therapy
|
|
09 Dec 2022 |
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
|
|
08 Dec 2022 |
Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
|
|
07 Dec 2022 |
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
|
|
05 Dec 2022 |
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
|
|
01 Dec 2022 |
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
|
|
30 Nov 2022 |
Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2
|
|
29 Nov 2022 |
Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress
|
|
23 Nov 2022 |
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
|
|
21 Nov 2022 |
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
|
|
18 Nov 2022 |
INOVIO Provides an Update on Lassa Fever and MERS Programs
|
|
18 Nov 2022 |
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
|
